Found Capital

Found Capital is a London-based early-stage venture capital firm backing technical founders building AI-driven enterprise software and next-generation drug discovery platforms. The firm operates with a focused thesis at the intersection of applied AI and deep technical innovation, supporting founders whose products require both technical sophistication and a credible commercial wedge to win.

The healthcare-relevant thesis covers AI/ML in healthcare, deep tech, and digital health, with an emphasis on companies leveraging machine learning, large models, and proprietary data infrastructure to create defensible technical moats. Drug discovery and clinical research tooling are particular areas of interest, alongside enterprise software targeted at healthcare and life sciences buyers. The firm is comfortable with the longer technical development timelines characteristic of AI-native life sciences companies and structures its engagement to match.

Found Capital invests at Seed and Series A with check sizes typically under $1M from initial position, with capacity for follow-on participation in subsequent rounds. Geographic focus is the United Kingdom and broader Europe, with active interest in technical founders coming out of academic research environments, prior AI operating roles, and the broader European technical ecosystem. Founders should expect a partner that engages substantively on technical strategy and is comfortable backing companies whose go-to-market thesis is still maturing alongside the technical platform.

The team brings backgrounds spanning venture investing, AI research and engineering, and operating roles at technical companies, which produces a diligence process that engages credibly on technical risk and machine learning architecture rather than treating these dimensions as black boxes. Decisions move through a focused partnership process, and the firm is candid about where conviction develops and where it does not, which founders consistently appreciate.

Found Capital’s working approach is hands-on, technically engaged, and oriented toward supporting founders through the specific challenges that AI-driven companies face. Portfolio founders describe partners who engage substantively on technical positioning, hiring, customer development, and follow-on fundraising strategy, with networks across the broader European AI and life sciences ecosystem that produce meaningful introductions. The firm’s appetite for technical risk is unusual among generalist European VCs and is one of the reasons it surfaces consistently in conversations among AI-native founders looking for a knowledgeable early partner. Reporting expectations are professional and aligned with early-stage venture norms, with quarterly engagement and active between-meeting collaboration on strategic questions. Found Capital will not be the right fit for founders building purely commercial software without meaningful technical depth or for those looking for a passive capital relationship. But for AI-driven enterprise software and drug discovery founders building in the United Kingdom or broader Europe who want a technically credible early-stage partner with the conviction to back ambitious technical bets and the engagement style to support founders through the specific challenges of building AI-native businesses, Found Capital represents a focused and increasingly relevant option in the European venture landscape.